These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20004791)

  • 1. Decitabine treatment of patients with higher-risk myelodysplastic syndromes.
    Steensma DP
    Leuk Res; 2009 Dec; 33 Suppl 2():S12-7. PubMed ID: 20004791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
    Yee KW; Jabbour E; Kantarjian HM; Giles FJ
    Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine.
    Hackanson B; Daskalakis M
    Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
    Pinto A; Zagonel V
    Leukemia; 1993 May; 7 Suppl 1():51-60. PubMed ID: 7683358
    [No Abstract]   [Full Text] [Related]  

  • 8. Azacitidine in lower-risk myelodysplastic syndromes.
    Santini V
    Leuk Res; 2009 Dec; 33 Suppl 2():S22-6. PubMed ID: 20004794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of decitabine as a prototype for an epigenetic drug program.
    Rosenfeld CS
    Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplasia: the good, the fair and the ugly.
    Schiffer CA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):49-55. PubMed ID: 17336254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine.
    Pitako JA; Haas PS; Van den Bosch J; Müller-Berndorff H; Kündgen A; Germing U; Wijermans PW; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():25-31. PubMed ID: 16292666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
    Gidwani R; Khan ZM; Fenaux P; Beach CL; Pashos CL
    J Med Econ; 2012; 15(1):145-54. PubMed ID: 21988635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
    Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
    Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
    Lee YG; Kim I; Yoon SS; Park S; Cheong JW; Min YH; Lee JO; Bang SM; Yi HG; Kim CS; Park Y; Kim BS; Mun YC; Seong CM; Park J; Lee JH; Kim SY; Lee HG; Kim YK; Kim HJ;
    Br J Haematol; 2013 May; 161(3):339-47. PubMed ID: 23432512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
    Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
    Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine: in myelodysplastic syndromes.
    McKeage K; Croom KF
    Drugs; 2006; 66(7):951-8. PubMed ID: 16740014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.